BrainCheck vs Creyos
Two digital cognitive assessment platforms with different claims to authority. BrainCheck's flagship is a regulated Class II device producing a structured cognitive result, paired with care planning so the score leads into a pathway rather than sitting on its own. Creyos comes from an academic lineage and its twelve task battery carries a large independent research base, applied broadly across cognitive and behavioural assessment and delivered as a link the patient completes anywhere. The distinction to hold is regulatory language: a clearance means a regulator reviewed performance, while a platform described as registered with the regulator has completed an administrative listing and nothing more. Neither publishes performance by education level, primary language or cultural background, which is the oldest known validity problem in cognitive testing and the one most likely to produce a wrong answer about a real patient.
- The flagship assessment is a regulated Class II device delivering a structured cognitive result, which is a higher bar than a validated questionnaire and matters when the output informs a dementia workup.
- Care planning sits alongside assessment, so the result leads somewhere rather than terminating in a score.
- For a primary care practice building a cognitive care pathway, the device status and the pathway support are both part of the purchase.
- The task battery has a large and genuinely independent research base behind it from its academic origins, which is unusual in this segment.
- Breadth is a real differentiator, with the same battery applied across cognitive and behavioural health assessment rather than one condition.
- Delivery is simple: a clinician sends a link and the patient completes the assessment in clinic or at home, with no device to deploy.
Side by Side
| Axis | B BrainCheck |
C Creyos |
|---|---|---|
| AI Centrality | ||
| Autonomy and Oversight Model | ||
| Model and Technology Transparency | ||
| Clinical and Operational Evidence | ||
| AI Safety and PHI Stewardship | ||
| HIPAA and BAA Posture | ||
| Security Certifications and Trust Center | ||
| FDA and Regulatory Status | ||
| AI Governance and Bias Disclosure | ||
| EHR and Interoperability Depth | ||
| Deployment Model and Data Residency | ||
| Commercial Transparency | ||
| Setting and Specialty Coverage |
Related comparisons
Other published head to head assessments involving these vendors or their closest peers. The full set for this category is on the Clinical Decision Support page.
Read the regulatory language carefully on both sides, because the words differ in meaning: a Class II device clearance is a review of the product's performance, while describing a platform as registered with the regulator refers to establishment listing, which is an administrative step and not a review of anything. Creyos publishes no security attestation, trust centre or pricing.
Neither vendor publishes performance by education, primary language or cultural background, which is the central validity question in cognitive testing, since these instruments are known to perform differently across those groups and a misclassification here starts a dementia workup or ends one prematurely.